Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 14.06%18.15B | 13.76%12.24B | 14.56%5.88B | 8.05%21.91B | 0.46%15.91B | -0.77%10.76B | -5.68%5.13B | 30.52%20.28B | 36.52%15.84B | 42.03%10.84B |
| Operating income | 13.76%12.24B | 8.05%21.91B | -0.77%10.76B | 30.52%20.28B | 42.03%10.84B | |||||
| Cost of sales | ---- | -14.85%-9.34B | ---- | -14.60%-17B | ---- | -1.54%-8.13B | ---- | -24.54%-14.83B | ---- | -37.67%-8.01B |
| Operating expenses | -14.85%-9.34B | -14.60%-17B | -1.54%-8.13B | -24.54%-14.83B | -37.67%-8.01B | |||||
| Gross profit | 10.65%4.33B | 10.40%2.9B | 11.81%1.43B | -9.80%4.91B | -9.15%3.91B | -7.29%2.63B | -3.96%1.28B | 50.13%5.45B | 59.51%4.31B | 56.00%2.83B |
| Selling expenses | ---- | -2.36%-576.31M | ---- | -1.90%-1.29B | ---- | -5.07%-563.04M | ---- | -35.30%-1.26B | ---- | -33.71%-535.87M |
| Administrative expenses | ---- | 11.08%-985.71M | ---- | 2.29%-2.16B | ---- | -14.53%-1.11B | ---- | -88.00%-2.21B | ---- | -71.97%-967.91M |
| Impairment and provision | ---- | -73.28%-93.85M | ---- | 42.30%-130.03M | ---- | 55.70%-54.16M | ---- | -158.44%-225.35M | ---- | -225.29%-122.25M |
| -Other impairment is provision | ---- | -73.28%-93.85M | ---- | 42.30%-130.03M | ---- | 55.70%-54.16M | ---- | -158.44%-225.35M | ---- | -225.29%-122.25M |
| Special items of operating profit | ---- | 61.16%589.89M | ---- | -53.36%313.76M | ---- | 18.60%366.04M | ---- | 8.16%672.73M | ---- | 9.28%308.62M |
| Operating profit | 44.78%1.83B | -31.86%1.65B | -16.42%1.27B | 17.83%2.42B | 38.12%1.51B | |||||
| Financing cost | ---- | -7.69%-122.05M | ---- | -44.31%-228.6M | ---- | -53.31%-113.33M | ---- | -20.04%-158.41M | ---- | -1.88%-73.92M |
| Share of profit from joint venture company | ---- | ---3.43M | ---- | --1.8M | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 30.44%2.21B | 48.13%1.71B | 47.07%820.98M | -37.12%1.42B | -19.17%1.69B | -20.00%1.15B | -21.08%558.22M | 17.67%2.26B | 43.92%2.1B | 40.69%1.44B |
| Tax | ---- | -149.46%-413.06M | ---- | 16.19%-353.41M | ---- | 35.65%-165.58M | ---- | -67.43%-421.7M | ---- | -131.07%-257.3M |
| After-tax profit from continuing operations | 31.13%1.29B | -41.92%1.07B | -16.59%986.96M | 10.17%1.84B | 29.66%1.18B | |||||
| Earning after tax | 26.63%1.7B | 31.13%1.29B | 30.57%635.55M | -41.92%1.07B | -22.25%1.34B | -16.59%986.96M | -24.75%486.74M | 10.17%1.84B | 33.59%1.73B | 29.66%1.18B |
| Minority profit | ---- | 99.54%-210K | ---- | 62.74%-33.62M | ---- | -145.62%-45.79M | ---- | -2,267.62%-90.24M | ---- | -373.09%-18.64M |
| Profit attributable to shareholders | 22.92%1.71B | 25.33%1.29B | 23.19%635.24M | -42.89%1.1B | -21.56%1.39B | -14.08%1.03B | -20.70%515.67M | 15.86%1.93B | 36.68%1.77B | 32.70%1.2B |
| Basic earnings per share | 25.81%0.39 | -44.83%0.32 | -18.42%0.31 | 9.43%0.58 | 31.03%0.38 | |||||
| Diluted earnings per share | 25.00%0.35 | -42.31%0.3 | -15.15%0.28 | 13.04%0.52 | 32.00%0.33 | |||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.